EVALUATION OF DRUG-DRUG INTERACTIONS OF VX-509 (DECERNOTINIB), AN ORAL SELECTIVE JANUS KINASE 3 INHIBITOR, IN HEALTHY HUMAN VOLUNTEERS

被引：2
|
作者：
Huang, J. [1 ]
Chavan, A. [1 ]
Viswanathan, L. [1 ]
Luo, X. [1 ]
Garg, V. [1 ]
Zhang, Y. [1 ]
Xi, Y. [1 ]
Kinnman, N. [1 ]
Mahnke, L. [1 ]
机构：
[1] Vertex Pharmaceut Inc, Boston, MA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.1184
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0135
引用
收藏
页码：225 / 226
页数：2
相关论文
共 50 条
  • [1] THE EFFECT OF DEUTERATION OF VX-509 (DECERNOTINIB) ON DRUG-DRUG INTERACTIONS (DDI) WITH MIDAZOLAM
    Huang, J.
    Yang, F.
    Yogaratnam, J.
    Shen, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 740 - 740
  • [2] Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases
    Farmer, Luc J.
    Ledeboer, Mark W.
    Hoock, Thomas
    Arnost, Michael J.
    Bethiel, Randy S.
    Bennani, Youssef L.
    Black, James J.
    Brummel, Christopher L.
    Chakilam, Ananthsrinivas
    Dorsch, Warren A.
    Fan, Bin
    Cochran, John E.
    Halas, Summer
    Harrington, Edmund M.
    Hogan, James K.
    Howe, David
    Huang, Hui
    Jacobs, Dylan H.
    Laitinen, Leena M.
    Liao, Shengkai
    Mahajan, Sudipta
    Marone, Valerie
    Martinez-Botella, Gabriel
    McCarthy, Pamela
    Messersmith, David
    Namchuk, Mark
    Oh, Luke
    Penney, Marina S.
    Pierce, Albert C.
    Raybuck, Scott A.
    Rugg, Arthur
    Salituro, Francesco G.
    Saxena, Kumkum
    Shannon, Dean
    Shlyakter, Dina
    Swenson, Lora
    Tian, Shi-Kai
    Town, Christopher
    Wang, Jian
    Wang, Tiansheng
    Wannamaker, M. Woods
    Winquist, Raymond J.
    Zuccola, Harmon J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (18) : 7195 - 7216
  • [3] VX-509 (Decernotinib) Is a Potent and Selective Janus Kinase 3 Inhibitor That Attenuates Inflammation in Animal Models of Autoimmune Disease
    Mahajan, Sudipta
    Hogan, James K.
    Shlyakhter, Dina
    Oh, Luke
    Salituro, Francesco G.
    Farmer, Luc
    Hoock, Thomas C.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2015, 353 (02): : 405 - 414
  • [4] VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions
    Zetterberg, Craig
    Maltais, Francois
    Laitinen, Leena
    Liao, Shengkai
    Tsao, Hong
    Chakilam, Ananthsrinivas
    Hariparsad, Niresh
    DRUG METABOLISM AND DISPOSITION, 2016, 44 (08) : 1286 - 1295
  • [5] VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
    Genovese, Mark C.
    van Vollenhoven, Ronald F.
    Pacheco-Tena, Cesar
    Zhang, Yanqiong
    Kinnman, Nils
    ARTHRITIS & RHEUMATOLOGY, 2016, 68 (01) : 46 - 55
  • [6] BIOMARKER ASSESSMENT OF VX-509, AN INVESTIGATIONAL SELECTIVE JAK3 INHIBITOR, IN HEALTHY VOLUNTEERS
    Catlett, I. M.
    Luo, X.
    Penney, M. S.
    Pray, M. E.
    Spencer-Green, G.
    Botfield, M.
    Hoock, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 203 - 203
  • [7] A PHASE 2B, 24-WEEK STUDY OF VX-509 (DECERNOTINIB), AN ORAL SELECTIVE JANUS KINASE 3 INHIBITOR, IN COMBINATION WITH BACKGROUND METHOTREXATE IN RHEUMATOID ARTHRITIS
    van Vollenhoven, R.
    Genovese, M. C.
    Zhang, Y.
    Kinnman, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 118 - 118
  • [8] A Phase 2b, 12-Week Study of VX-509, an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis
    Genovese, Mark C.
    van Vollenhoven, Ronald
    Bloom, Bradley J.
    Jiang, John G.
    Kinnman, Nils
    ARTHRITIS AND RHEUMATISM, 2013, 65 (12): : 3320 - 3320
  • [9] Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers
    Topletz-Erickson, Ariel
    Lee, Anthony
    Rustia, Evelyn L.
    Sun, Hao
    Mayor, JoAl G.
    Abdulrasool, Layth, I
    Walker, Luke
    Endres, Christopher J.
    CLINICAL PHARMACOKINETICS, 2022, 61 (10) : 1417 - 1426
  • [10] EVALUATION OF DRUG-DRUG INTERACTIONS OF PEMIGATINIB (INCB054828) IN HEALTHY VOLUNTEERS.
    Ji, T.
    Rockich, K.
    Epstein, N.
    Chen, X.
    Punwani, N.
    Yeleswaram, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S83 - S84
12345